Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels

For patients with locally advanced prostate cancer, combined treatment with chemotherapy and hormonal therapy offers extended control of prostate-specific antigen (PSA) levels, compared to hormonal therapy alone, reports a study in the April issue of The Journal of Urology, an Official Journal of the American Urological Association.

Augmedix Reports $10.8M Revenue in Q2 2023

August 8, 2023

‘Ancient DNA’ tools and 23andMe database uncover African American ancestries of thousands

New research that combines technology to sequence “ancient DNA” with direct-to-consumer genetic testing has identified tens of thousands people alive today who are genetically linked

August 3, 2023

John Maraganore’s RNAi biotech City Therapeutics debuts with $135M Series A

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.